41st week of 2009 patent applcation highlights part 32 |
Patent application number | Title | Published |
20090252633 | LOBE PUMP SYSTEM AND METHOD OF MANUFACTURE - A method of manufacturing a rotor to be used in a dual-rotor lobe pump system for pumping a material at a periodic rate is provided. The method includes selecting a desired periodic flow rate for the material, selecting a number of lobes for the rotor, and selecting either a thickness of the rotor or a spacing between the dual-rotors' axes of rotation in the lobe pump. The method also includes determining the profile for the rotor based on the desired periodic flow rate, so that when the rotor is operated within the dual-rotor lobe pump system, the material can be pumped at substantially the desired periodic flow rate. In another embodiment of the invention, a lobe pump rotor profile is formed by the method described above. | 2009-10-08 |
20090252634 | METALLIC POWDER MIXTURES - The invention relates to mixtures of metal, alloy or composite powders which have a mean particle diameter D50 of not more than 75 μm, preferably not more than 25 μm, and are produced in a process in which a starting powder is firstly deformed to give platelet-like particles and these are then comminuted in the presence of milling aids together with further additives and also the use of these powder mixtures and shaped articles produced therefrom. | 2009-10-08 |
20090252635 | Process For Producing Sintered Porous Materials - The invention provides a process of making porous structures or materials, including the colloidal processing (e.g. slip casting, pressure casting, tape casting or electrophoretic deposition) of solid particle emulsions to form a green body that can be directly sintered without a de-binding step. | 2009-10-08 |
20090252636 | POWDERED METAL ALLOY COMPOSITION FOR WEAR AND TEMPERATURE RESISTANCE APPLICATIONS AND METHOD OF PRODUCING SAME - A powder metal steel alloy composition for high wear and temperature applications is made by water atomizing a molten steel alloy composition containing C in an amount of at least 3.0 wt %; at least one carbide-forming alloy element selected from the group consisting of: Cr, V, Mo or W; an O content less than about 0.5 wt %, and the balance comprising essentially Fe apart from incidental impurities. The high carbon content reduces the solubility of oxygen in the melt and thus lowers the oxygen content to a level below which would cause the carbide-forming element(s) to oxidixe during water atomization. The alloy elements are thus not tied up as oxides and are available to rapidly and readily form carbides in a subsequent sintering stage. The carbon, present in excess, is also available for diffusing into one or more other admixed powders that may be added to the prealloyed powder during sintering to control microstructure and properties of the final part. | 2009-10-08 |
20090252637 | JOINING OF DIFFICULT-TO-WELD MATERIALS AND SINTERING OF POWDERS USING A LOW-TEMPERATURE VAPORIZATION MATERIAL - The present invention discloses a process for sintering particles using a sintering aid. The sintering aid can be brought into contact with a plurality of particles to be sintered such that a mixture of the particles and the sintering aid is provided. The mixture of particles and the sintering aid is heated and at least part of the sintering aid is vaporized. Sintering of the particles to form a sintered component followed by cooling of the sintered component can complete the process, or in the alternative, a subsequent heating step or steps can be included whereby additional vaporization of the sintering aid can occur. | 2009-10-08 |
20090252638 | Cost-effective titanium alloy powder compositions and method for manufacturing flat or shaped articles from these powders - The invention relates to the cost-effective manufacture of near-net shape titanium articles from sintered powders containing titanium and all required alloying elements. The cost-effective initial powder composition for subsequent room temperature consolidation and sintering contains: (a) 10-50 wt. % of underseparated titanium powder with ≦500 μm in particle size manufactured from underseparated titanium sponge comprising up to 2 wt. % of chlorine and up to 2 wt. % of magnesium. The underseparated titanium powder costs significantly less than that for fully separated powder of completely reduced sponge; (b) 10-90 wt. % of hydrogenated titanium powder, whereby this powder is a mixture of two hydrogenated powders A and B containing different amount of hydrogen: powder A contains amount of hydrogen in the range of 0.2-1 wt. % and powder B contains amount of hydrogen in the range of 2-3.9 wt. %. The powder with high hydrogen content provides purification of underseparated titanium powder during heat treatment and sintering, while the powder with low hydrogen content provides sufficient strength of green compacts as well as perfect structure and quality of the final sintered article; (c) 0-90 wt. % of standard grade refined titanium powder, and/or 5-50 wt. % of alloying metal powders: master alloys or elemental powders. The method includes (a) mixing said underseparated titanium powder, the C.P. titanium powder, the hydrogenated titanium powders containing different amount of hydrogen, (b) compacting the obtained blend by room temperature consolidation such as die pressing, molding, direct powder rolling, cold isostatic pressing, and/or metal injection molding to density at least 60% of the theoretical density, (c) additional crushing titanium hydride powders into fine fragments during consolidation at the pressure of 400-960 MPa to provide forming a uniform network of fine pores promoting healing effects during sintering, chemical cleaning and refining titanium powders in the compacted articles by heating to 300-900° C. and holding for at least 30 minutes to provide a reaction of Cl, Mg, and oxygen, with hydrogen emitted due to decomposition of titanium hydride, (e) heating in vacuum for sintering in β-phase zone of titanium in the temperature range of 1000-1350° C. and holding for at least 30 minutes, and cooling. The new technology allows the purity and mechanical properties of sintered titanium alloys and the manufacture of near-net shape sintered titanium articles to be controlled by a cost-effective process. | 2009-10-08 |
20090252639 | METALLURGICAL POWDER COMPOSITION AND METHOD OF PRODUCTION - An annealed prealloyed water atomised iron-based powder is provided which is suitable for the production of pressed and sintered components having high wear resistance. The iron-based powder comprises 15-30% by weight of Cr, 0.5-5% by weight of each of at least one of Mo, W and V, and 0.5-2%, preferably 0.7-2% and most preferably 1-2% by weight of C. The powder has a matrix comprising less than 10% by weight of Cr, and comprises large chromium carbides. A method for production of the iron-based powder also is provided. | 2009-10-08 |
20090252640 | STEEL ALLOY, A HOLDER OR A HOLDER DETAIL FOR A PLASTIC MOULDING TOOL, A TOUGH HARDENED BLANK FOR A HOLDER OR HOLDER DETAIL, A PROCESS FOR PRODUCING A STEEL ALLOY - A steel alloy is described that, in weight-%, includes 0.08-0.19 C, where 0.16≦C+N≦0.28, 0.1-1.5 Si, 0.1-2.0 Mn, 13.0-15.4 Cr, 0.01-1.8 Ni, 0.01-1.3 Mo, max. 0.7 V, max. 0.25 S, max. 0.01 Ca, max. 0.01 O, in order to improve the machinability of the steel, and balance iron and unavoidable impurities, wherein the steel alloy has a microstructure which, in a tough hardened condition, comprises a martensitic matrix with up to 30 vol-% ferrite. | 2009-10-08 |
20090252641 | Hot-Rolled Steel Sheet, Method for Making the Same, and Worked Body of Hot-Rolled Steel Sheet - A steel sheet contains, in terms of percent by mass, C: 0.01 to 0.2%, Si: 2.0% or less, and Mn: 3.0% or less and has a martensite phase as dominant phase and ferrite with a grain size of 20 μm or less as a second phase. The ferrite is contained in area ratio of 1% to 30% and the amount of solute carbon being 0.01 percent by mass of more. The steel sheet can provide a hot-rolled steel sheet suitable for automobile steel sheet, i.e., has excellent press workability and excellent strain aging property whereby the tensile strength significantly increases by heat treatment at about the same temperature as typical baking process after the press-working. Moreover, hardening of the ferrite phase improves the fatigue strength after the strain aging. | 2009-10-08 |
20090252642 | Aluminum alloy sheet for lithographic printing plate and method of producing the same - An aluminum alloy sheet for a lithographic printing plate which allows pits to be more uniformly formed by an electrochemical surface-roughening treatment and exhibits more excellent adhesion to a photosensitive film and water retention properties, and a method of producing the same are disclosed. The aluminum alloy sheet includes 0.1 to 1.5% of Mg, more than 0.05% and 0.5% or less of Zn, 0.1 to 0.6% of Fe, 0.03 to 0.15% of Si, 0.0001 to 0.10% of Cu, and 0.0001 to 0.05% of Ti, with the balance being aluminum and impurities, the Mg content and the Zn content satisfying a relationship “4×Zn %−1.4%≦Mg %≦4×Zn %+0.6%”, and the amount of aluminum powder on the surface of the aluminum alloy sheet being 0.1 to 3.0 mg/m | 2009-10-08 |
20090252643 | METAL TREATMENT TO ELIMINATE HOT TEAR DEFECTS IN LOW SILICON ALUMINUM ALLOYS - An aluminum alloy and a method of casting. At least one of zirconium, scandium, a nucleating agent selected from the group consisting of metal carbides, aluminides and borides, and rare earth elements are added to the alloy while in the molten state such that upon solidification, the cast alloy exhibits improved hot tear resistance. In a particular form, the nucleating agent may be titanium diboride for grain refining. Other agents that can be used for grain refining include scandium, zirconium, silicon, silver and one or more rare earth elements. In the case of rare earth elements, mischmetal may be used as a precursor. Combinations of titanium diboride and at least one other agent are especially effective in reducing the incidence of hot tearing in products cast from the modified aluminum alloy. | 2009-10-08 |
20090252644 | DENTAL ALLOY AND USE THEREFORE - The invention relates to a dental alloy consisting of 20 to 35% chromium, 0 to 10% molybdenum, 0 to 3% manganese, 0.5 to 2% tin, 2 to 10% gallium, 2 to 8% indium, 0 to 8% silicon, 1.5 to 15% tungsten, 0.1 to 2% aluminum, cobalt as remainder, and impurities, and to the use of the dental alloy for the machining production of dental superstructures, in particular crowns, bridges and combined dental prostheses. | 2009-10-08 |
20090252645 | METHOD FOR FILTERING ODORS OUT OF AN AIR FLOW, AND FILTERING DEVICE EQUIPPED WITH AN ODOR FILTER - A method for filtering odors out of an air flow during which an air flow containing odorous substances is guided through a filtering device equipped with an odor filter, whereby the odor filter has activated carbon or a similar substance serving as filtering material. As an additional method step, the inventive method provides that the particles contained in the air flow are at least partially ionized and/or dissociated before entering the odor filter. | 2009-10-08 |
20090252646 | STERILIZATION METHODS AND SYSTEMS FOR GAMING EQUIPMENT - Enclosures that include light generating sterilization sources and conveying systems for sterilizing gaming items are disclosed. Also disclosed are gaming equipment or tables having user interface portions coated or treated with a photo-catalyst for maintaining sterility of the user interface. | 2009-10-08 |
20090252647 | COMPOSITIONS AND METHODS FOR APPLYING ANTIMICROBIALS TO SUBSTRATES - Methods and compositions are provided that control spread of pathogens and prevent infections. In various embodiments, a liquid impervious substrate having an antimicrobial disposed thereon is provided. In one embodiment, a method of antimicrobially treating a substrate is provided, comprising contacting the substrate with an effective amount of a water stable composition, comprising i) water; ii) a product that is formed by reacting in water: a) an organosilane of the formula R | 2009-10-08 |
20090252648 | Apparatus and methods for treating allograft products - There are disclosed systems and methods of delivering sterile fluids aseptically to a sealed canister. In an embodiment, a includes a canister having an inlet, a vent, and a drain outlet, a reagent manifold in communication with the inlet, a bubbler in communication with the vent, and a fluid communicator from the drain outlet. In another embodiment, a method includes providing a canister having an inlet, a vent, and a drain outlet; selectively providing reagents to the canister from a reagent manifold in communication with the inlet, allowing excess gasses to leave the canister with a bubbler in communication with the vent, and selectively purging the reagents from the canister through the drain outlet. Other embodiments are also disclosed. | 2009-10-08 |
20090252649 | Apparatus for body fluid analysis using surface-textured optical materials - A variety of characteristics of body fluid may be measured by introducing a sample to a textured surface on optical material such as waveguides and sheets. The textured surface presents a field of elongated projections which are spaced apart to exclude certain components of the body fluid sample from entering into the spaces between the projections, while permitting other parts of the body fluid sample which contains the analyte to enter into those spaces. The analyte contacts a chemistry on the surface which is sensitive to the analyte, whereupon the analyte and the analyte-sensitive chemistry interact in a manner that is optically detectable. The optical material is packaged in suitable structures such as elongated cylinders, flat test strips, and sheets. A structure containing the optical material is mounted on a detector, which both illuminates the optical material and detects and analyzes the light that returns from the textured surface. | 2009-10-08 |
20090252650 | PORTABLE MEMS-BASED SPECTRAL IDENTIFICATION SYSTEM - A sensing arrangement detects a compound of interest within a gas sample. An amplifying fluorescent polymer produces an output signal that varies in response to an interaction of the amplifying fluorescent polymer with the compound of interest. Additionally, an infrared illumination source produces infrared electromagnetic energy that causes the amplifying fluorescent polymer to generate the output signal. A MEMS detector is positioned to receive the output signal generated by the amplifying fluorescent polymer, and produces an output electrical signal that is responsive to an interaction between the compound of interest and the amplifying fluorescent polymer. The output electrical signal is responsive to a quenching of the output signal of the amplifying fluorescent polymer. A pattern database stoics pattern data corresponding to characteristics of compounds of interest. | 2009-10-08 |
20090252651 | MICROFLUIDIC DEVICE AND METHOD OF FABRICATING THE SAME - A microfluidic device and a method of fabricating the microfluidic device are provided. The microfluidic device includes: a platform including an upper substrate and a lower substrate that are bonded to face each other; a microfluidic structure obtained by forming grooves in the lower substrate; a lower substrate protrusion pattern including an outline protrusion that protrudes from the lower substrate toward the upper substrate along an outline of the microfluidic structure; and an adhesive layer disposed between the lower substrate protrusion pattern and the upper substrate in order to bond the upper substrate and the lower substrate to each other. The lower substrate protrusion pattern only supports the upper substrate, and remaining portions of the lower substrate except for the lower substrate protrusion pattern do not have structures for supporting the upper substrate. | 2009-10-08 |
20090252652 | Apparatus And Method For Handling Fluids For Analysis - A reaction vessel with a bottom drain opening supporting a selected unpressured head of fluid by the surface tension of the fluid. A device processing zone includes a support for spaced rows of reaction vessels, passages communicating with their drain openings of supported vessels, and a pressure source for selectively draining fluid through the drain openings. Generally horizontal bar magnets are supported for selected vertical movement between the vessel rows. A dispensing head has X discharge openings selectively positionable over X selected reaction vessels. A metering pump mechanism selectively meters X a selected quantity of fluid a bulk supply (where X is at least four), and selectively pumps the metered selected quantities through the drain openings to the selected reaction vessels. Methods of drawing fluid from the vessels using the pressure source, and moving the magnets to form a pellet of analyte are also included. | 2009-10-08 |
20090252653 | FLUID REFORMING APPARATUS - A fluid reforming apparatus of the present invention includes: a flow channel ( | 2009-10-08 |
20090252654 | AIR CLEANER - An air cleaner includes a photo-catalyst filter, a light source and an ozone generator. The light source is configured for emitting light having a given wavelength to activate the photo-catalyst layer to decompose contaminants thereon. The ozone generator is configured for generating ozone flowing through the photo-catalyst layer to promote decomposition of the contaminants on the photo-catalyst layer. | 2009-10-08 |
20090252655 | PHOTO-CATALYST AIR CLEANER - A photo-catalyst air cleaner includes at least one light source, a photo-catalyst filter and a first water supply. The photo-catalyst filter includes a hydrophilic substrate with a layer formed on a surface of the substrate exposed to light from the at least one light source. The water supply is configured for supplying water for absorption by the substrate, thereby humidifying surfaces of the photo-catalyst filter. | 2009-10-08 |
20090252656 | Air-cleaning decorative humidifier - An air-cleaning decorative humidifier, including mainly a support seat, a water receptacle, at least a shaft, a fan, and a water sub-receptacle; in which a base seat of the water receptacle is fixed to the bottom of the water receptacle; a first water opening is provided on the base seat of the water receptacle; a water valve is provided on the first water opening; the fan and the water sub-receptacle are provided in the support seat; a water level control rod is provided in the water sub-receptacle; the shaft is connected with at least a decoration directly or through a mechanism. | 2009-10-08 |
20090252657 | Slurry phase polymerisation process - A process comprising polymerising an olefin monomer optionally together with an olefin comonomer in the presence of a polymerisation catalyst in a diluent in a loop reactor which comprises at least 2 horizontal sections and at least 2 vertical sections to produce a slurry comprising solid particulate olefin polymer and the diluent wherein the Froude number in at least 20% of the length of the vertical sections of the reactor loop is less than 85% of the Froude number in at least 20% of the length of the horizontal sections of the loop is disclosed. | 2009-10-08 |
20090252658 | Loading/Unloading of Particulates to/from Microchannel Reactors - The invention providing methods of loading and unloading particulate from microchannels in apparatus that contains multiple microchannels, typically apparatus that is designed to operate with hundreds or thousands of particulate-containing microchannels. Aligning a sonicating head at one end of a set of microchannels provides a particularly effective mode for densifying particulate in microchannels. | 2009-10-08 |
20090252659 | METHOD AND APPARATUS FOR FLUE GAS TREATMENT - A method for flue gas treatment includes causing a combustion in a boiler using at least a part of a flue gas emitted from a gas turbine and introduced from at least one of an upstream side and a downstream side of an exhaust heat recovery boiler, which recovers a high-temperature heat of the flue gas, so as to increase a concentration of carbon dioxide in the flue gas, and recovering carbon dioxide in a carbon dioxide recovery apparatus. | 2009-10-08 |
20090252660 | PYROLYSIS FURNACE AND PROCESS TUBES - A cracking furnace construction includes a firebox defining a chamber having a high emissivity thermal protective coating disposed on at least part of the refractory walls and/or on process tubes disposed within the chamber. The coating contains an inorganic adhesive for metal/alloy tubes or colloidal silica and/or colloidal alumina for refractory walls or ceramic tubes, a filler, and one or more emissivity agents. A method of coating the firebox chamber includes preparing the surface of the tubes/refractory walls, preparing the coating, and applying the coating to the surface. | 2009-10-08 |
20090252661 | Fuel reformer - A fuel reformer includes a reforming portion having a tubular catalytic converter that is composed of a substrate supporting the catalytic component, and is arranged to have a center axis extending along the supply direction of the fuel and oxidizer derived from a supply portion, and a communication passage arranged along an inner wall of the catalytic converter and communicating with the supply portion. The fuel and oxidizer supplied from the supply portion to the communication passage pass from the inner wall of the catalytic converter to an outer wall thereof by forced convection, thereby reforming the fuel. | 2009-10-08 |
20090252662 | Process for purifying inorganic materials - The invention relates to a process for purifying inorganic materials by treating the materials with a solution of hydrogen fluoride in aqueous hydrofluorosilicic acid. The process involves treating an inorganic material containing at least two species, to at least partially separate a first species contained in the material from a second species contained in the material, and comprises treating the material with a fluorine acid solution comprising aqueous hydrofluorosilicic acid and hydrofluoric acid (HF), such that the first species is converted to a product selected from the group consisting of a fluoride, a fluorosilicate and mixtures thereof, and such that the second species is at least partly unreacted, and separating the second species from the product. | 2009-10-08 |
20090252663 | Method and system for the removal of an elemental trace contaminant from a fluid stream - A method for the removal of an elemental trace contaminant from a fluid stream, which comprises:
| 2009-10-08 |
20090252664 | METHODS AND APPARATUS FOR HEATING REAGENTS AND EFFLUENTS IN ABATEMENT SYSTEMS - In some aspects, an apparatus for abating effluent from an electronic device manufacturing process tool is provided, including: a reaction chamber adapted to receive an effluent; and a reagent heating apparatus in fluid connection with the reaction chamber; wherein the reagent heating apparatus is adapted to heat a reagent and to introduce the heated reagent into a heated reagent reaction zone of the reaction chamber; and wherein the reaction chamber is further adapted to mix the effluent and the heated reagent in the heated reagent reaction zone. Other apparatus and methods are disclosed. | 2009-10-08 |
20090252665 | ENHANCEMENT OF CONVENTIONAL SCR AND SNCR PROCESSES WITH AMMONIA DESTRUCTION CATALYST - An apparatus and method for achieving increased NO | 2009-10-08 |
20090252666 | FLUORIDE DRYING METHOD - The invention relates to methods and apparatus for drying [ | 2009-10-08 |
20090252667 | RARE EARTH-ACTIVATED ALUMINUM NITRIDE POWDERS AND METHOD OF MAKING - Rare earth-activated aluminum nitride powders are made using a solution-based approach to form a mixed hydroxide of aluminum and a rare earth metal, the mixed hydroxide is then converted into an ammonium metal fluoride, preferably a rare earth-substituted ammonium aluminum hexafluoride ((NH | 2009-10-08 |
20090252668 | Methods For Preparing Iron Source Material And Ferrous Oxalate for Lithium Ferrous Phosphate - Methods for preparing iron source material and ferrous oxalate for lithium ferrous phosphate are disclosed. One method comprises bringing solution containing ferrite and soluble non-ferrous metal salts in contact with oxalate solution; wherein said method of contact is to allow a flow of the ferrite solution containing ferrite and soluble non-ferrous metal salts to come in contact with a flow of oxalate solution. Another method comprises brings a stream of ferrite solution in contact with a stream of oxalate solution, wherein the flow rates of the ferrite solution and oxalate solution give the resulting slurry a pH of 2-6. The ferrous oxalate particles produces by the methods of the present invention are regularly shaped and have small and evenly distributed diameters. Lithium ferrous phosphate made from iron source material and ferrous oxalate prepared using the methods of the present invention has small particle diameter, homogeneous particle size, good electrical conductivity, and superior electrochemical properties. | 2009-10-08 |
20090252669 | SYNTHESIS OF TETRAGONAL PHASE STABILIZED NANO AND SUBMICRON SIZED NANOPARTICLES - Novel, monodispersed, spherical ZrO | 2009-10-08 |
20090252670 | HYDROGEN GENERATOR - A hydrogen generator includes a container with multiple concentric hollow cylinders of chemical hydride fuel disposed within the container. A water vapor source is disposed within the container and operable to deliver water vapor to the cylinders of chemical hydride fuel. Generated hydrogen is provided via a hydrogen output port formed in the container. | 2009-10-08 |
20090252671 | ALUMINUM-ALKALI HYDROXIDE RECYCLABLE HYDROGEN GENERATOR - An aluminum-alkali hydroxide recyclable hydrogen generator is provided that enables generation of hydrogen for a consuming apparatus on demand. The hydrogen generator includes a source of aluminum, a source of a hydroxide, a source of water, and a reaction chamber, where the amount of at least one of the aluminum, sodium hydroxide, and water that is introduced into the reaction chamber is used to limit the chemical reaction to control the amount of hydrogen generated. | 2009-10-08 |
20090252672 | NASAL DELIVERY OF THERAPEUTIC AGENTS USING TIGHT JUNCTION AGONISTS - The invention relates to a therapeutic composition comprising a therapeutically effective amount of one or more therapeutic agents and a nasal mucosa absorption-enhancing amount of one or more tight junction agonists. The invention further relates to a method of treating a subject comprising intranasally administering the composition of the invention to the subject. | 2009-10-08 |
20090252673 | Methods of Making and Using Rubidium-81-Containing Compositions - The present invention relates to preparation of imaging compositions containing Rubidium-81. In addition, the present invention relates to uses of Rubidium-81-containing compositions in diagnostic imaging such as, for example, myocardial imaging. | 2009-10-08 |
20090252674 | Tripodal Ligands with the Coordinating Motifs K2 -BH2 or K3 -BH3 Relevant for Biomedical Applications of Organometallic Complexes - The present invention relates to a compound for use as a chelator in the radioactive labeling of biomolecules with metal tricarbonyl complexes, which compound has the general Formula (I) wherein M is a monovalent cation, such as Li, Na, K, Tl, Rb, Cs or an alkyl ammonium; R1 is H, alkyl, aryl or a biomolecule; R2 is H or a pendant arm, said pendant arm optionally comprises a biomolecule, with the proviso that when R1 is H, R2 is not H or COOH, and when R1 is alkyl or aryl, R2 is not H. | 2009-10-08 |
20090252676 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS - The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter. | 2009-10-08 |
20090252677 | Probes for In Vivo Targeting of Active Cysteine Proteases - Activity-based probes, which are specific for certain active cysteine proteases (caspase, cathepsin and legumain) and carry radioactive labels, are disclosed. The present probes comprise an acyloxymethyketone (AOMK) “warhead” that binds only to active enzyme. The probes further comprise peptide-like structure that targets the probe to a specific cysteine protease or protease family, and a radiolabel on the probe, which is bound to the targeted enzyme. It has been found that the present probes are stable in vivo and give specific target images distinguishable over background. The preferred probes are labeled with a positron-emitting agent such as | 2009-10-08 |
20090252678 | COX-2-TARGETED IMAGING AGENTS - The presently disclosed subject matter provides a method for synthesizing a radiological imaging agent by reacting a COX-2-selective ligand with a compound comprising a detectable group, wherein the COX-2-selective ligand is a derivative of a non-steroidal anti-inflammatory drug (NSAID) comprising an ester moiety or a secondary amide moiety. Also provided are compositions that are synthesized using the method, as well as methods of using the compositions of the presently disclosed subject matter. | 2009-10-08 |
20090252679 | Novel Compound Having Affinity for Amyloid - The present invention provides a compound which has affinity with amyloid, shows sufficiently rapid clearance from normal tissues and is suppressed in toxicity such as mutagencity. Provided is a compound represented by the following formula (1) or a salt thereof: | 2009-10-08 |
20090252680 | NOVEL COMPOUND WITH AFFINITY FOR AMYLOID - A compound represented by the following formula or a salt thereof: | 2009-10-08 |
20090252681 | Nanobodies and Polypeptides Against EGFR and IGF-IR - The invention relates to polypeptides and Nanobodies against Epidermal Growth Factor Receptor (EGFR) and/or Insulin Growth Factor-I Receptor (IGF-IR). The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such Nanobodies, polypeptides, nucleic acids and/or host cells; and to uses of such Nanobodies, polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 2009-10-08 |
20090252682 | IN-VIVO OPTICAL IMAGING METHOD INCLUDING ANALYSIS OF DYNAMIC IMAGES - In-vivo optical molecular imaging methods for producing an image of an animal are described. A time series of image data sets of an optical contrast substance in the animal is acquired using an optical detector Each image data set is obtained at a selected time and has the same plurality of pixels, with each pixel having an associated value. The image data sets are analyzed to identify a plurality of distinctive time courses, and respective pixel sets are determined from the plurality of pixels which correspond to each of the time courses. In one embodiment, each pixel set is associated with an identified anatomical or other structure, and an anatomical image map of the animal can be generated which includes one or more of the anatomical structures. | 2009-10-08 |
20090252683 | Composition Comprising Cross-Species-Sepecific Antibodies and uses Thereof - The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of said bispecific anti-bodies exhibiting cross-species specificity. The present invention also relates to methods of measuring the biological activity and/or efficacy of such bispecific antibodies exhibiting cross-species specificity. In addition, the present invention relates to pharmaceutical compositions comprising bispecific single chain antibodies exhibiting cross-species specificity and to methods for the preparation of pharmaceutical compositions comprising said bispecific single chain antibodies exhibiting cross-species specificity for the treatment of diseases. | 2009-10-08 |
20090252684 | Determination of tissue-specific profile of amino acid requirements form the relationship between the amounts of tRNAs for individual amino acids and the protein-bound amino acid profile of the tissue - Systems and methods by which optimal profiles of amino acids for specific tissues can be determined. The results of these systems and methods can then be sued to generate medical nutrition products targeting specific tissues either to enhance growth of specific tissues by providing complementary amino acids in a nutritional supplement or pharmaceutical composition form. They can also be used to generate similar medical nutrition products to inhibit growth of particular tissues, such as those that are cancerous | 2009-10-08 |
20090252685 | HIGH PENETRATION PRODRUG COMPOSITIONS OF PROSTAGLANDINS AND RELATED COMPOUNDS - The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of prostaglandins or prostaglandin analogs which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent prostaglandins or prostaglandin analogs after crossing the biological barrier and thus can render treatments for the conditions that the parent prostaglandins or prostaglandin analogs can. Additionally, the HPPs are capable of reaching areas that parent prostaglandins or prostaglandin analogs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate. | 2009-10-08 |
20090252686 | Ex Vivo Hyperpolarization of Imaging Agents - The present invention generally relates to methods for accelerating the ex vivo induction of nuclear hyperpolarization in imaging agents. | 2009-10-08 |
20090252687 | ASYMMETRIC FLUORO-SUBSTITUTED POLYMETHINE DYES - The present invention relates to improved conjugates of biological molecules with an improved class of water-soluble, green to near infra-red (NIR) cyanine labelling dyes. The dyes are asymmetric fluoro-substituted polymethines, and exhibit a high degree of photostability and reduced dye-dye quenching, as well as a high fluorescence quantum yield. The conjugates are useful for in vivo optical imaging, as well as fluorescence detection methods. Also disclosed are pharmaceutical compositions containing the conjugates, kits for the preparation of such compositions, and methods of in vivo imaging using the conjugates. | 2009-10-08 |
20090252688 | Magnetic resonance contrast medium containing an iron-binding protein - An inventive principle of at least one embodiment is based on linking an iron-binding functionality in the form of a bacterial iron-binding protein to a binding element which specifically recognizes a biological structure, in order to increase a local detectable increase in the concentration of the contrast medium. In at least one embodiment of the invention, a magnetic resonance contrast medium is provided which is capable of binding by way of a binding element to a biological structure in the body of a mammal, the binding element including an isolated polypeptide. The polypeptide includes a first amino acid sequence of a bacterial iron-binding protein or a derivative thereof, wherein the bacterial iron-binding protein or said derivative thereof has an iron-binding activity. In at least one embodiment, the binding element can bind a protein. In at least one embodiment, the binding element can have a ligand for a cellular membrane protein, a ligand for a cellular glycoprotein, an antibody or an antigen-binding fragment of an antibody and/or can bind a tumor antigen. | 2009-10-08 |
20090252689 | Hair styling composition - There is provided a hair styling composition comprising
| 2009-10-08 |
20090252690 | Flavoured Mouth Wash Composition - The present invention provides a flavoured product comprising four or more flavour materials having antimicrobial properties and selected from the group comprising nonanol, decanol, nonanal, decanal, amyl propionate, anethole synthetic, anisic aldehyde, basil oil, benzyl benzoate, benzyl butyrate, benzyl formate, chamomile oil, cinnamic aldehyde, cis-3-hexenol, clove bud oil, damascone, ethyl acetoacetate, eucalyptus oil, ginger, isoamyl acetate, menthol laevo, methyl cinnamate, methyl salicylate, orange oil, rosemary oil, tarragon, Tea Tree oil, and peppermint oil: and one or more antimicrobial agents selected from the group comprising triclosan, pyrophosphates, zinc salts, cetylpyridinium chloride, parabens, stannous salts, sodium dodecyl sulphate, chlorhexidine, copper salts, strontium salts, peroxides and sanguinarine. | 2009-10-08 |
20090252691 | FOAM MANIPULATION COMPOSITIONS CONTAINING FINE PARTICLES - A foam manipulation stabilizing composition for use in consumer products includes a plurality of surface-modified particles in combination with at least one surfactant. The particles have an average particle size greater than 100 nm up to about 50 μm and a hydrophobicity measured by a contact angle between about 20° to 140°. The ratio of particles-to-surfactant may be between about 1:20 to about 20:1. The surface modification may include grafting pH or temperature switching functional groups to the particles or to a composition, such as a polymer, coated on the particle. A method for reducing the level of foam in a rinse solution is also described. | 2009-10-08 |
20090252692 | ESTERIFIED FATTY ACID COMPOSITION - The invention is directed to compositions comprising lecithin, olive oil, esterified fatty acids and mixed tocophenols for use in the treatment and prevention of various types of arthritis and other inflammatory joint conditions, periodontal diseases and psoriasis, which avoid many of the side effects associated with known treatments. The compositions of the present invention have the advantage of increased stability, a reduction of arachidonic acid in cells, a reduction in eicosanoid production and enhanced cell regulation and communication. Also disclosed are methods for using the compositions for treatment and prevention. | 2009-10-08 |
20090252693 | Process For Preparing Dispersions Of TiO2 In The Form Of Nanoparticles, And Dispersions Obtainable With This Process And Functionalization Of Surfaces By Application Of TiO2 Dispersions - A process for preparing nanoparticulate dispersions of TiO | 2009-10-08 |
20090252694 | Novel Chalcone Derivatives, Pharmaceutically Acceptable Salt, Method for Preparation and Uses Thereof - Disclosed relates to a novel chalcone derivative, pharmaceutically acceptable salt thereof, a method for preparing the same and uses thereof, the chalcone derivative being readily obtained through the steps of: reacting aminoacetophenone with sulfonylchloride under the presence of an appropriate salt; and reacting the compound prepared in the above step with hydroxybenzaldehide under the presence of an appropriate catalyst. The chalcone derivative of formula 1 in accordance with the present invention having strong enzyme inhibitory activities for glycosidase can be effectively used in preventing and treating various diseases induced by glycosidase, and the chalcone derivative of the invention having tyrosinase and melanin synthesis inhibitory activities can be effectively used as a skin-whitening compound. | 2009-10-08 |
20090252695 | SPECIAL EFFECTS WITH MIXTURES OF INTERFERENCE PIGMENTS - A method of producing mixtures of interference pigments having special effects comprises mixing at least one large particle size interference pigment with at least one normal size interference pigment of predetermined colors and in proportions desired to obtain a unique effect. | 2009-10-08 |
20090252696 | Hair Straightening Composition Comprising Urea - An aqueous based hair straightening composition having a pH from 12 to 14 comprising i) an hydroxide ion generator; and ii) from 0.5 wt % to 20 wt % of the total composition of urea in which the weight ratio of urea to hydroxide generator is greater than 1:1. | 2009-10-08 |
20090252697 | METHOD FOR PERMANENTLY RESHAPING KERATIN FIBERS WITH AN ACID PRE-TREATING COMPOSITION - A method for permanently reshaping keratin fibers, such as hair, comprising applying onto the keratin fibers a pre-treating composition comprising, in a cosmetically acceptable medium, at least one entity chosen from non reducing inorganic acids, non reducing organic acids, and salts thereof, wherein the pH value of said pre-treating composition ranges from 2 to 5; rinsing the keratin fibers; applying onto the keratin fibers a treating composition comprising, in a cosmetically acceptable medium, at least one hydroxide compound; and reshaping the keratin fibers, wherein the reshaping occurs after applying the pre-treating composition and at any time before, during, or after applying the treating composition. | 2009-10-08 |
20090252698 | EMULSION COMPOSITIONS FOR EYELASHES - The invention relates to emulsion compositions for application to eyelashes containing at least one surfactant comprising silicone, hydrocarbon and glycerol group(s), as well as to methods of applying such compositions to eyelashes and kits containing such compositions. | 2009-10-08 |
20090252699 | MEDICAL DEVICES WITH AN ANTIMICROBIAL POLYURETHANE COATING - The present invention relates to a medical device comprising a coating which is obtainable starting from a solution comprising a nonionic polyurethaneurea and silver. | 2009-10-08 |
20090252700 | Hydroxyphenyl cross-linked macromolecular network and applications thereof - A synthetic nucleus pulposus is provided that is useful in treatment of degenerative disc disease, augmentation of a degenerate disc, and alleviation of back pain. In an embodiment the synthetic nucleus pulposus comprises hyaluronan macromolecules that have been cross-linked via dihydroxyphenyl linkages. The synthetic nucleus pulposus restores or improves the water-retention capability of the disc. A method of treating an intervertebral disc with the cross-linked hyaluronan macromolecules is also provided. A method of regenerative therapy to address loss of cells of nucleus pulposus of an intervertebral disc based on treatment with the cross-linked hyaluronan macromolecules and mesenchymal stem cells is also provided. | 2009-10-08 |
20090252701 | Biostatic Polymer - Methods and compositions effective for at least a week for prevention of microbial colony growth on a surface, for example an inanimate surface, where the surface is covered with a dry or substantially dry film formed from a composition comprising a polyvinyl alcohol and a quaternary ammonium compound. The film may be formed in situ by coating the surface with a solution or emulsion comprising a polyvinyl alcohol and a quaternary ammonium compound and then causing or allowing it to dry or substantially dry. | 2009-10-08 |
20090252702 | POLYMER-BASED ANTI-CANCER AGENTS - The present invention relates to the use of amphiphilic block copolymers for treating and preventing cancer, and in particular by reducing the proliferation rate of cancer cells. Preferred block copolymers comprises a central hydrophobic chain, preferably a polypropylene oxide chain, two which at least two hydrophilic side chains, preferably polyethylene oxide chains, are connected. | 2009-10-08 |
20090252703 | Use of alcohol co-solvents to improve pegylation reaction yields - Disclosed is a method of producing a composition of matter. The method involves obtaining a pharmacologically active peptide; and conjugating the peptide to a pharmaceutically acceptable polyethylene glycol (PEG) by reacting the peptide with a PEG-aldehyde compound at a free amine moiety on the peptide in a buffer solution comprising an alcohol co-solvent. | 2009-10-08 |
20090252704 | THERAPIES FOR COGNITION AND LEARNING ENHANCEMENT - The invention relates to a combination comprising an amount of an NO donor, such as ISDN, and/or an amount of another pharmaceutical agent that enhances neurotransmission or which acts as neuroprotectants such as memantine, clomethiazole and tacrine. These compositions can be used in producing cognition and learning enhancement, whereby the invention also provides for a new method of treatment of Alzheimer's disease and related neurodegenerative disorders. | 2009-10-08 |
20090252705 | IL-6/IL-6R Fusion Protein - The present invention relates to a fusion protein comprising a functional IL-6 molecule and a functional DS-sIL-6R molecule. The present invention also relates to a nucleic acid encoding the fusion protein, methods of producing the fusion protein, and the use of the fusion protein in the treatment of infectious diseases and in inflammatory and immunological disorders. | 2009-10-08 |
20090252706 | Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer - The invention relates to compounds of formula (I) wherein Ra is —C(O)ORI, in which R1 is 1-7C-alkyl. 3-7C-cycloakyl, 1-7C-alkyl substituted by Raa, or 2-7C-alkyl substituted by Rab and Rac on different carbon atoms, Rb is -T-Q, in which T is 1-6C-alkylene or 3-7C-cycloalkylene, and Q is substituted by Rba and Rbb and Rbc, and is phenyl, which are useful for the therapy of hyperproliferative diseases, in particular human cancer. | 2009-10-08 |
20090252707 | NOVEL EXPRESSION VECTORS AND USES THEREOF - A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells. | 2009-10-08 |
20090252708 | Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof - Biotherapeutic compositions of a non-pathogenic bacterial strain such as M-17 and its substrains and an anaerobic bacterial antibiotic such as metronidazole, are disclosed. Further disclosed are uses of M-17 or its substrains and an anaerobic bacterial antibiotic for treating disorders caused by anaerobic bacteria, whereby such disorders include, for example, pouchitis, microbial infection, irritable bowel syndrome, inflammatory bowel disease, mucous colitis and diarrhea. | 2009-10-08 |
20090252709 | NOVEL BACTERIUM BELONGING TO THE GENUS BIFIDOBACTERIUM AND UTILIZATION OF THE SAME - It is intended to provide | 2009-10-08 |
20090252710 | TUMOR SUPPRESSION USING HUMAN PLACENTAL PERFUSATE AND HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS - Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. | 2009-10-08 |
20090252711 | Stem Cells And Methods Of Making And Using Stem Cells - The invention provides a method of making a pluripotent stem cell from a cell that is not pluripotent, such as from a differentiated stem cell or a lineage-restricted stem cell. The methods comprise culturing the starting cell in the presence of one or more epigenetic altering agents, such as a histone deacetylase inhibitor and/or a DNA methyltransferase inhibitor. Pluripotent stem cells are also provided, as are methods of treating or preventing a disease, disorder, or condition in a mammal using the cells. | 2009-10-08 |
20090252712 | CHIMERIC C3-LIKE RHO ANTAGONIST BONE THERAPEUTIC - Methods of treating bone disorders in a subject in need thereof by administering to said subject a therapeutically effective amount of a Rho antagonist are disclosed. | 2009-10-08 |
20090252713 | CIRCULAR DNA MOLECULE HAVING A CONDITIONAL ORIGIN OF REPLICATION, PROCESS FOR THEIR PREPARATION AND THEIR USE IN GENE THERAPY - A circular DNA molecule, useful for gene therapy, comprising at least one nucleic acid sequence of interest, characterised in that the region allowing the replication thereof has an origin of replication with a functionality in a host cell that requires the presence of at least one specific protein foreign to said host cell. A method for preparing same, cells incorporating said DNA molecules and uses thereof in gene therapy are also described. | 2009-10-08 |
20090252714 | Autoantigenes for Improved Diagnosis, Prognosis and Treatment of Inflammatory Neurological Diseases - According to the invention, autoantibodies, the appearance of which is characteristic of neurological autoimmune diseases, especially multiple sclerosis, are detected and the respective autoantigens identified. It can further be shown that many of these autoantigens are expressed specifically in the brain. The identification of the autoantigens and autoantibodies is useful for diagnosis and treatment. A brain-specific expression of the autoantigens further emphasizes an important role of the antigens and antibodies in the origin and development of neurological autoimmune diseases. | 2009-10-08 |
20090252715 | IMMORTALIZATION OF MAMMALIAN CELLS - Genomic instability in T antigen expressing cells can be overcome by modifying the gene expressing T antigen so that it lacks Bub1 binding. Stable cell lines can be produced by incorporation of the modified T antigen gene, preferably together with the catalytic sub-unit of the telomerase construct. | 2009-10-08 |
20090252716 | METHODS FOR IDENTIFYING NUCLEAR RECEPTOR/LIGAND COMBINATIONS FOR TARGETING BRAIN TUMOR STEM CELLS AND FOR THEIR USE - An in vitro method is provided for identifying nuclear receptors abnormally expressed by brain tumor stem cells and a corresponding ligand which, if administered to brain tumor stem cells (BTSC's), is capable of inhibiting cell proliferation. Once the nuclear receptor/ligand combination has been identified, it can be utilized in vitro and in vivo to inhibit the proliferation and survival of the cancerous stem cells and ultimately affect proliferation and survival of tumors. The method can be utilized alone or in combination with other treatment methods. The method can also be utilized with regard to other forms of cancer which have cancerous stem cells associated therewith and which abnormally express one or more nuclear receptors. | 2009-10-08 |
20090252717 | Compositions and Methods for Treating Polyglutamine-Expansion Neurodegenerative Diseases - The invention relates to methods for stimulating fast axonal transport in polyglutamine expansion diseases and treating polyglutamine expansion diseases by inhibiting SAPK-dependent phosphorylation of kinesin. The present invention also provides methods for identifying agents which inhibit the phosphorylation of the kinesin, as well as methods for monitoring treatment of a polyglutamine expansion disease based on the phosphorylation of serine 176 of kinesin-1A or kinesin-1C, or serine 175 of kinesin-1B. | 2009-10-08 |
20090252718 | Phospholipase(s) and Use(s) Thereof - The invention relates to phospholipase(s), isoforms, derivatives, mutants and/or fragments thereof, for the preparation of a medicament for the treatment and/or prevention of ischemia. Preferred is the use of secretory phospholipase, particularly phospholipase A | 2009-10-08 |
20090252719 | USE OF FRUCTANASES IN FEED OF HOOFED ANIMALS, PREFERABLY TO PREVENT DISEASES - Laminitis is defined as an inflammation of the sensitive laminae of the hoof, especially in horses. It has been surprisingly found that fructanases such as 2,1-β-D-fructan hydrolase are highly effective as therapeutic and prophylactic agents against laminitis in horses. The fructanases may be used as enzyme compositions in horse feed, as additives for horse feed or as oral preparations for the therapy and prophylaxis of laminitis. Because of its effectiveness in hydrolyzing fructans, which seem to play an important role in the aetiology of laminitis, the administration of fructanases in combination with an increased intake of fructans or with an increased availability of fructans is particularly advantageous. | 2009-10-08 |
20090252720 | Prolonged FIX Analogues and Derivatives - The invention is related to FIX analogues which have an increased circulation time in the blood stream before activation compared to that that of native FIX (and a week after injection to a patient retains at least about 5% of the FIX activity compared to the initial activity peak value reached after injection). The claimed FIX analogues comprise an inserted cysteine residue which has been further modified by conjugation with a chemical group increasing the molecular weight of the FIX analogue. | 2009-10-08 |
20090252721 | Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer - The invention relates to agents and methods for the diagnosis, prognosis and treatment of cancer. Specifically, the invention relates to the use of nucleic and amino acid sequences encoding transmembrane superfamily member 6 (TM4SF6), synaptophysin like protein (SYPL), stomatin like 2 (STOML2), Ras related GTP binding protein RAGA), nucleotide sensitive chloride channel 1A (CLNS1A), prion protein (p27-30) (PRNP), guanine nucleotide binding protein beta 2-like 1 (GNB2L1), guanine nucleotide binding protein 4 (GNG4), integral membrane protein 2B (ITM2B), integral membrane protein 1 (ITM1), transmembrane 9 superfamily member 2 (TM9SF2), opiate receptor-like 1 protein (OPRL1), low density lipoprotein receptor-related protein 4 (LRP4), human glomerular epithelial protein 1 (GLEPP1), toll-like receptor 3 (TLR3), and/or zona pellucida glycoprotein 3A (ZP3) for the diagnosis of both early and late stage non-steroid specific cancers, cancer prognosis, as well as screening for therapeutic agents that regulate the gene expression and/or biological activity of said proteins. This invention further relates to the biological technologies designed to inhibit the gene expression and/or biological activity of said proteins including using agents identified in screening assays described herein, vector delivery of antisense polynucleotide sequences, and antibody targeting of said proteins. In specific embodiments, the proteins are of human origin. | 2009-10-08 |
20090252722 | Botulinum Neurotoxin a Protein Receptor and Uses Thereof - The invention relates to a polypeptide comprising an amino acid sequence, at least 70 percent of which are identical to the amino acid sequence of the synaptic vesicle glycoprotein of | 2009-10-08 |
20090252723 | Remedy for endometriosis - The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient. | 2009-10-08 |
20090252724 | Antibodies Against Amyloid Beta 4 With Glycosylated in the Variable Region - The present invention relates to a purified antibody molecule preparation being characterized in that at least one antigen binding site comprises a glycosylated asparagine (Asn) in the variable region of the heavy chain (V | 2009-10-08 |
20090252725 | Use of CD23 Antibodies to Treat Malignancies in Patients with Poor Prognosis - The invention relates to methods of treating B-cell chronic lymphocytic leukemia, and other CD23 | 2009-10-08 |
20090252726 | ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND METHODS OF USE THEREOF - The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:FVIIa complex, effectively preventing factor X or FIX binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site. Also provided are humanized antibodies and fragments thereof that bind to the TF. | 2009-10-08 |
20090252727 | GLUCAGON RECEPTOR ANTAGONISTS - The present invention relates to glucagon receptor polypeptide antagonists which inhibit the binding of the hormone glucagon to its receptor. More particularly, the present invention relates to high affinity glucagon receptor antibodies or Fab fragments thereof that inhibit binding of glucagon to its receptor and their use in the treatment or prevention of type 2 diabetes (NIDDM) and related disorders in mammalian species. | 2009-10-08 |
20090252728 | NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS - The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof. | 2009-10-08 |
20090252729 | Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto - The present invention features inter alia polypeptides comprising an Fc region comprising genetically-fused Fc moieties. In addition, the instant invention provides, e.g., methods for treating or preventing a disease or disorder in subject by administering the binding polypeptides of the invention to said subject. | 2009-10-08 |
20090252730 | METHODS OF TREATING SKIN DISORDERS USING AN IL-31RA ANTAGONIST - The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist. | 2009-10-08 |
20090252731 | Multivalent Carriers of Bi-Specific Antibodies - Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the association of a targetable construct with two or more bi-specific antibodies. The targetable constructs and targetable complexes of the invention are incorporated into biosensors, kits and pharmaceutical compositions, and are used in a variety of therapeutic and other methods. | 2009-10-08 |
20090252732 | VARIABLE REGION SEQUENCES OF IL-31 MONOCLONAL ANTIBODIES AND METHODS OF USE - The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention provides the hybridomas that generate the monoclonal antibodies and the amino acid sequences of the variable regions of the monoclonal antibodies and chimeric antibodies comprising the amino acid sequences of the light and heavy chain variable regions. | 2009-10-08 |
20090252733 | Generation and Profiling of Fully Human Gold-Derived Therapeutic Antibodies Specific for Human CD38 - The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma. | 2009-10-08 |